Sign in
CompletedPhase 3

Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin

Key facts

Who runs it
Avexima Diol LLC
Where
Russia8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
215 people enrolled
Started
22 Jul 2024
Ended
14 Jan 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Sodium enoxaparin
  • Dimolegin
  • Dimolegin placebo
  • Sodium enoxaparine placebo
Record updated
16 January 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Men and women between the ages of 18 and 80
  • Patients scheduled for unilateral elective total hip or knee arthroplasty
  • The patient's voluntary informed consent
  • Negative pregnancy test result (for female patients with preserved reproductive potential)
  • Patients with reproductive potential should agree to use methods of contraception according to the protocol

Who cannot take part

  • Surgery for an acute fracture (<4 weeks)
  • Collection of at least one volume unit of donated blood (≥ 450 ml) or blood transfusion during the previous 12 weeks
  • Surgery or injury during the last 90 days
  • Significant cardiovascular diseases currently or within 6 months prior to screening
  • The need for continuous use of antiplatelet drugs, which cannot be discontinued at least 4 days before the start of the investigational therapy
  • Systemic therapy with drugs with strong inducers and inhibitors of CYP3A4 and P-glycoprotein, which cannot be discontinued at least 7 days before the start of the investigational therapy
  • Participation in another clinical trial currently or within 90 days prior to screening
  • Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; non-compliance with the study therapy or procedures
  • Increased risk of thrombosis
  • Active bleeding or increased risk of bleeding
  • Diseases of the digestive system that may disrupt the absorption of the study drug
  • Active liver or biliary tract diseases
  • Positive test result for HIV, syphilis, hepatitis B and C markers
  • The development of trophic disorders of the lower extremities that are not amenable to drug treatment
  • Any condition in which, in the opinion of the researcher, surgical intervention or the use of anticoagulants is contraindicated
  • Creatinine clearance, calculated according to the Cockcroft-Gault formula, less than 30 ml/min
  • Hemoglobin < 105 g/l in women or < 115 g/l in men
  • Abnormal results aboratory parameters of the coagulation system (platelets, APTT, prothrombin time, INR) beyond the limits of normal values
  • An increase in ALT or ACT ≥ 2 times from the upper limit of normal (ULN) or total bilirubin ≥ 1.5 times from ULN
  • Hypersensitivity or contraindications to the administration of Dimolegin®, enoxaparin sodium, unfractionated heparin or warfarin
  • Revision or extraction arthroplasty
  • Septic arthritis
  • The only lower limb
  • Current coagulopathy (patient's or his relative's) or congenital thrombophilia
  • Body mass index is less than 18.5 or more than 40 kg/m2
  • Body weight for women is less than 45 kg, for men less than 57 kg and above 130 kg for both
  • Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >110 mmHg
  • The need for constant use of parenteral or oral anticoagulants
  • Pregnant or breast-feeding women
  • Affiliation to a research center, Sponsor, or contractual research organization

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The study will assess the incidence of VTE, VTE-related mortality, and all-cause mortality during different follow-up periods in both treatment groups. Additionally, the study will evaluate the frequency of bleeding events and the incidence, number, and characteristics of all adverse events associated with Dimolegin® and Clexane® therapy.

The 2 groups in the trial

  • 1 (Dimolegin® Group)Treatment being tested

    Subgroup 1A (Hip Arthroplasty): Dimolegin® + placebo Clexane® for 35±2 days. Subgroup 1B (Knee Arthroplasty): Dimolegin® + placebo Clexane® for 14±1 days.

    Treatment: Dimolegin and Sodium enoxaparine placebo

  • 2 (Clexane® Group)Existing treatment, for comparison

    Subgroup 2A (Hip Arthroplasty): Clexane® + placebo Dimolegin® for 35±2 days. Subgroup 2B (Knee Arthroplasty): Clexane® + placebo Dimolegin® for 14±1 days.

    Treatment: Sodium enoxaparin and Dimolegin placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized, Double-blind, Double-masked Prospective Multicenter Trial to Evaluate the Efficacy and Safety of the Oral Anticoagulant Dimolegin® Compared With Low Molecular Weight Heparin (Clexane®) as a Means of Preventing VTE in Patients Undergoing Elective Endoprosthetics of Large Joints
Record updated
16 January 2026